Loading...
StemCyte Differentiator2018-11-30T16:02:56+00:00

StemCyte Differentiator

Global Presence

  • StemCyte Inc. USA was established in 1997. More than instead of greater than 20 years experience in cord blood banking.

  • Global footprint with operations in USA, Taiwan and India.

  • StemCyte India is a joint venture of StemCyte Inc.(USA), Apollo Hospitals and Cadila Pharmaceuticals.

  • The Apollo and Cadila partnership More than instead of greater than 20 instead of 68 years of experience in the health service industry.

Highest Quality & Standards

  • StemCyte is the highest accredited stem cell bank – FACT, AABB, ISO, NABL, WHO-GMP, FDA

  • USFDA approved collection bag, freezing bag, canisters, etc. are truly imported

  • FDA approved insulated kit box is fire resistant and tough

  • Our endeavor is to ensure that we meet the highest quality accredited standards by following 400 SOPs diligently

  • 24/7 customer support at all stages – collection, testing, storage, retrieval and transplantation

‘Hybrid+’ Model

  • Public Bank – The UCB is donated to StemCyte for processing & storage for further use by unrelated patients

  • Private Bank – UCB is collected, processed & stored solely for the future medical needs of the child or the family

  • Advanced Therapeutics – Treatment of patients in need

  • Clinical Trials – Use of cord blood stem cells in indications like spinal cord injuries, stroke, etc.

Plasma Depletion Technique

  • One of the most important aspects in cord blood transplantation is the recovery of stem cells

  • StemCyte’s patented plasma depletion technology ensures upto 99.96% cell recovery

  • Patient transplanted with plasma depleted cord blood receive

    • Higher cell dose
    • Lower transplant related mortality
    • Superior engraftment
    • Overall survival
    • Higher rate of Survival

StemCyte’s International Experts

  • Dr. Wise Young, (M.D, PhD)
    Chief Medical Director

    “Extensive work on spinal cord injury”

  • Dr. Lawrence D. Petz, (M.D.)
    Global Medical Director

    “Proven cord blood stem cell transplant for treatment of HIV”

  • Dr. Tang-Her Jaing
    Associate Professor,
    Division of Hematology, Oncology, Department of Pediatrics, Chang Gung Children’s Hospital, Taiwan

    “More than 120 transplants for Thalassemia”

Clinical Trials & Research by StemCyte’s Experts

  • StemCyte is actively involved in clinical trials and research studies, to further the science of saving lives using cord blood stem cells and cord tissue

  • Current clinical trials are as follows:

    • Spinal cord injury
    • Stroke
    • HIV
    • Cardiac repair
    • Optic nerve
    • Autism
    • Cerebral Palsy
    • Ischemia

Transplant Experience: Unmatched in the Industry

  • StemCyte : The most experienced cord blood bank

    • Has participated in more than 2084 transplants across 315 transplant centers in 38 countries on 6 continents
    • Facilitators of 47 transplants in India, within a span of 6 years??
  • “Click below link to get the complete details of transplants done by StemCyte India:”

LIST OF TRANSPLANT WORLDWIDE
TRANSPLANT  RECORD OF INDIA

StemCyte’s Unit is sufficient to treat Adult patients

  • 5 million cells are required to treat 1 Kg body weight – reference PCGB

  • StemCyte’s Unit has Avg TNC count of 120 * 107

  • Stemcyte has treated a patient with 75 kg body with using 1 single Unit

 StemCyte is the only company to treat RARE diseases

  • StemCyte has treated HLH : 22 patients worldwide and 2 in India

  • StemCyte India has treated 1 patient of CEP

  • StemCyte has also treated Hurler’s syndrome, Mucopolysaccharidosis (MPS) and Mylodisplastic Syndrome (MDS)

  • StemCyte has experience in overall treating 58 diseases

StemCyte Does a Chemical free processing

  • PD technology is does not use HES or any other chemical

  • USE of HES can increase mortality if used in cord blood

  • The European EMA made the decision that hydroxyethyl starch (HES) should no longer be used in patients with sepsis or burn injuries, or in critically ill patients (EMA, 2015) (15).

  • FDA warns to use HES for processing of cord blood (Reference FDA website)